Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 10,802 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Terminated No phase listed Observational

Advancing the Science of Pediatric Interstage Home Monitoring

NCT06547268
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Wireless sensor and platform
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 2 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 25, 2026, 6:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

High Risk Multiple Gestation Study

NCT02278874
View directory record Official record
Conditions
Trisomy 13, Trisomy 18, Trisomy 21, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Glen Cove, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

NCT03196297
View directory record Official record
Conditions
Haemostasis, Haemophilia A
Interventions
Concizumab, Turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Extension Study of PRX-102 for up to 60 Months

NCT01981720
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa)
Biological
Lead sponsor
Protalix
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

NCT05437120
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 25, 2026, 6:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

NCT05669950
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Lu AG13909
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 25, 2026, 6:19 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

NCT00688597
View directory record Official record
Conditions
Pompe Disease
Interventions
Duvoglustat
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 25, 2026, 6:19 PM EDT
Completed No phase listed Observational

Evaluation of Patients With Known or Suspected Heart Disease

NCT00001313
View directory record Official record
Conditions
Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

NCT06813924
View directory record Official record
Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Not applicable Interventional

Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women

NCT03046355
View directory record Official record
Conditions
Fetal Growth Restriction
Interventions
Labor induction at 37.0 to 37.6 weeks of gestation, Expectant monitoring until delivery
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores

NCT02779426
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Text messages
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Up to 6 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

NCT05737485
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
RCT1100
Drug
Lead sponsor
ReCode Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 6:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mm

NCT07224308
View directory record Official record
Conditions
Laxity; Skin
Interventions
Ultherapy Prime
Device
Lead sponsor
The Levine Center for Plastic Surgery
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997
View directory record Official record
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03738397
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab, Placebo to dupilumab, Placebo to upadacitinib
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 76 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Food Effect Study of 3 Types of Carisbamate

NCT04520360
View directory record Official record
Conditions
Healthy Subjects
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 25, 2026, 6:19 PM EDT
Active, not recruiting Phase 4 Interventional

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

NCT05003648
View directory record Official record
Conditions
Adrenoleukodystrophy, Restless Legs Syndrome
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Not applicable Interventional

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

NCT05573685
View directory record Official record
Conditions
Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
Interventions
DiNaMo Study App, Placebo App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 25, 2026, 6:19 PM EDT
Terminated No phase listed Observational

Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies

NCT02226315
View directory record Official record
Conditions
Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Oct 25, 2026, 6:19 PM EDT
Terminated Not applicable Interventional Results available

Vitamin D Deficiency and Atopic Dermatitis

NCT01337635
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency
Interventions
Vitamin D
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

NCT03566017
View directory record Official record
Conditions
Fabry Disease
Interventions
pegunigalsidase alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 25, 2026, 6:19 PM EDT
Completed Phase 2 Interventional

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

NCT03864068
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions
Placebo, Inositol
Other · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 25, 2026, 6:19 PM EDT
Not listed Not applicable Interventional

Baselines in Reproductive Disorders

NCT00456274
View directory record Official record
Conditions
Amenorrhea, Hypogonadotropic Hypogonadism, Kallmann's Syndrome
Interventions
Frequent baseline blood sampling
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 25, 2026, 6:19 PM EDT
Active, not recruiting Not applicable Interventional

PREEMIE: Study for Treatment of PDA in Premature Infants

NCT06587282
View directory record Official record
Conditions
Patent Ductus Arteriosus (PDA)
Interventions
Bloom Micro Occluder System
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
5 Days and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Sacramento, California • San Diego, California • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 6:19 PM EDT